Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)).
Description | Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). |
Targets&IC50 | p120γ:1 nM, p110α:0.1 nM, p110δ:2.9 nM |
In vitro | Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K/Akt signaling pathway. It may cause inhibition of tumor cell growth and survival in susceptible tumor cell populations [3]. |
Synonyms | PX-866 |
Molecular Weight | 525.59 |
Formula | C29H35NO8 |
CAS No. | 502632-66-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sonolisib 502632-66-8 PI3K/Akt/mTOR signaling PI3K PX 866 PX-866 PX866 inhibitor inhibit